B. Riley Wealth Advisors Inc. Takes $84,000 Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

B. Riley Wealth Advisors Inc. acquired a new position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 14,746 shares of the biotechnology company’s stock, valued at approximately $84,000.

A number of other hedge funds have also recently made changes to their positions in AUPH. Banque Cantonale Vaudoise lifted its stake in Aurinia Pharmaceuticals by 126.6% during the second quarter. Banque Cantonale Vaudoise now owns 9,684 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 5,410 shares in the last quarter. Virtu Financial LLC acquired a new position in Aurinia Pharmaceuticals during the 1st quarter worth about $78,000. China Universal Asset Management Co. Ltd. boosted its holdings in Aurinia Pharmaceuticals by 67.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 27,802 shares of the biotechnology company’s stock valued at $139,000 after acquiring an additional 11,189 shares during the period. Capstone Investment Advisors LLC acquired a new position in Aurinia Pharmaceuticals in the 1st quarter valued at about $158,000. Finally, PFG Investments LLC increased its stake in Aurinia Pharmaceuticals by 37.9% during the second quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock worth $164,000 after purchasing an additional 7,900 shares during the period. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 price objective on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, September 6th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Aurinia Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $10.00.

Insider Transactions at Aurinia Pharmaceuticals

In other news, insider Scott Michael Habig sold 18,249 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total transaction of $96,902.19. Following the completion of the sale, the insider now owns 456,338 shares in the company, valued at approximately $2,423,154.78. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH opened at $6.98 on Friday. The firm has a market capitalization of $995.79 million, a price-to-earnings ratio of -16.23 and a beta of 1.44. The firm’s fifty day simple moving average is $6.61 and its 200-day simple moving average is $5.78. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.05. The company has a current ratio of 5.33, a quick ratio of 4.82 and a debt-to-equity ratio of 0.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. The company had revenue of $57.10 million for the quarter, compared to analysts’ expectations of $54.25 million. Aurinia Pharmaceuticals had a negative return on equity of 11.84% and a negative net margin of 24.31%. Aurinia Pharmaceuticals’s quarterly revenue was up 37.6% on a year-over-year basis. During the same period last year, the firm earned ($0.08) earnings per share. Equities analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.13 EPS for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.